893422-47-4

Basic information

• Product Name: 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one
• Synonyms: 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one;Akti_2008;Akt1 and Akt2-IN-1;3-phenyl-2-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-1,6-naphthyridin-5(6H)-one
• CAS NO: 893422-47-4
• Molecular Formula: C₃₃H₂₉N₇O
• Molecular Weight: 539.64
• Mol File: 893422-47-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one(893422-47-4)
• EPA Substance Registry System: 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one(893422-47-4)

Safety Data

• Hazardous Substances Data: 893422-47-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one is used as a potential pharmaceutical candidate for [specific application reason] due to its complex molecular structure and the presence of aromatic rings and nitrogen-containing heterocycles, which may contribute to its biological activity.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one serves as a subject of study for exploring its potential as a receptor ligand or enzyme inhibitor, given its structural features that may confer biological activity.

Upstream product

• 893423-70-6 5-methoxy-3-phenyl-2-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl-1,6-naphthyridine 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 105-07-7 4-cyanobenzaldehyde 
• 893423-70-6 C₃₄H₃₁N₇O 
• 187834-88-4 tert-butyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate 
• 66739-89-7 4-(1,3-dioxolan-2-yl)benzonitrile 
• 868280-61-9 1-[4-(1,3-dioxolan-2-yl)phenyl]-2-phenylethanone 
• 893423-62-6 tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate 
• 14432-12-3 4-Amino-2-chloropyridine 
• 100-70-9 2-Cyanopyridine 
• 234108-73-7 (2-chloro-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 893423-65-9 2-[4-(1,3-dioxolan-2-yl)phenyl]-5-methoxy-3-phenyl-1,6-naphthyridine 

Downstream Products

• 917363-80-5 5-chloro-3-phenyl-2-{4-[4-(5-pyridin-2-yl-4H-[1,2,4]triazol-3-yl)-piperidin-1-ylmethyl]-phenyl}-[1,6]naphthyridine 
• 917363-80-5 5-chloro-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917363-81-6 (3-phenyl-2-{4-[4-(5-pyridin-2-yl-4H-[1,2,4]triazol-3-yl)-piperidin-1-ylmethyl]-phenyl}-[1,6]naphthyridin-5-yl)-hydrazine 
• 917363-81-6 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917359-62-7 9-phenyl-8-(4-{[4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)[1,2,4]triazolo[3,4-f]-1,6-naphthyridine 

Relevant articles and documents

Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model

A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One molecu

Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors

This paper describes the improvement of cell potency in a class of allosteric Akt 1 and 2 inhibitors. Key discoveries include identifying the solvent exposed region of the molecule and appending basic amines to enhance the physiochemical properties of the

INHIBITORS OF AKT ACTIVITY

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

INHIBITORS OF AKT ACTIVITY

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.